Page 152 - 2020_07-Haematologica-web

G. Cario et al.
Imatinib after induction for treatment of
children and adolescents with Philadelphia- chromosome positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open- label, intergroup study. Lancet Oncol. 2012; 13(9):936-945.
14. Biondi A, Cario G, De Lorenzo P, et al. Long-term follow up of pediatric Philadelphia positive acute lymphoblastic leukemia treated with the EsPhALL2004 study: high white blood cell count at diag- nosis is the strongest prognostic factor. Haematologica. 2019;104(1):13-16.
15. Biondi A, Gandemer V, De Lorenzo P, et al. Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010): a prospective, intergroup, open-label, single- arm clinical trial. Lancet Haematol. 2018; 5(12):641-652.
16. Schultz KR, Bowman WP, Aledo A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-posi- tive acute lymphoblastic leukemia: a chil- dren’s oncology group study. J Clin Oncol. 2009;27(31):5175-5181.
17. Schultz KR, Carroll A, Heerema NA, et al. Long-term follow-up of imatinib in pedi- atric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children’s Oncology Group Study AALL0031. Leukemia. 2014;28(7):1467-1471.
18. Slayton WB, Schultz KR, Kairalla JA, et al. Dasatinib plus intensive chemotherapy in children, adolescents, and young adults with philadelphia chromosome-positive acute lymphoblastic leukemia: results of Children’s Oncology Group Trial AALL0622. J Clin Oncol. 2018;36(22):2306- 2314.
19. Roberts KG, Yang Y, Turner DP, et al. Oncogenic role and therapeutic targeting of ABL-class and JAK-STAT activating kinase alterations in Ph-like ALL. Blood Adv. 2017;1(20):1657-1671.
20. Den Boer ML, van Slegtenhorst M, De Menezes RX, et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classi- fication study. Lancet Oncol. 2009;10(2):125-134.
21. Roberts KG, Li Y, Payne-Turner D, et al. Targetable kinase-activating lesions in Ph-
like acute lymphoblastic leukemia. N Engl J
Med. 2014;371(11):1005-1015.
22. Arber DA, Orazi A, Hasserjian R, et al. The
2016 revision to the World Health Organization classification of myeloid neo- plasms and acute leukemia. Blood. 2016; 127(20):2391-2405.
23. Boer JM, Koenders JE, van der Holt B, et al. Expression profiling of adult acute lym- phoblastic leukemia identifies a BCR- ABL1-like subgroup characterized by high non-response and relapse rates. Haematologica. 2015;100(7):261-264.
24. Harvey RC, Mullighan CG, Wang X, et al. Identification of novel cluster groups in pediatric high-risk B-precursor acute lym- phoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. Blood. 2010; 116(23):4874-4884.
25. van der Veer A, Waanders E, Pieters R, et al. Independent prognostic value of BCR- ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. Blood. 2013;122(15):2622-2629.
26. Roberts KG, Pei D, Campana D, et al. Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease. J Clin Oncol. 2014;32(27):3012-3020.
27. Boer JM, Steeghs EM, Marchante JR, et al. Tyrosine kinase fusion genes in pediatric BCRABL1-like acute lymphoblastic leukemia. Oncotarget. 2017;8(3):4618- 4628.
28. Reshmi SC, Harvey RC, Roberts KG, et al. Targetable kinase gene fusions in high-risk B-ALL: a study from the Children’s Oncology Group. Blood. 2017; 129(25):3352-3361.
29. Dworzak MN, Buldini B, Gaipa G, et al. AIEOP-BFM consensus guidelines 2016 for flow cytometric immunophenotyping of Pediatric acute lymphoblastic leukemia. Cytometry B Clin Cytom. 2018;94(1):82- 93.
30. van der Velden VH, Cazzaniga G, Schrauder A, et al. European Study Group on MRD detection in ALL (ESG-MRD- ALL). Analysis of minimal residual disease
by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia. 2007;21(4):604-611.
31. van der Does-van den Berg A, Bartram CR, Basso G, et al. Minimal requirements for the diagnosis, classification, and evaluation of the treatment of childhood acute lym- phoblastic leukemia (ALL) in the “BFM Family” Cooperative Group. Med Pediatr Oncol. 1992;20(6):497-505.
32. Reshmi SC, Harvey RC, Roberts KG, et al. Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group. Blood. 2017; 129(25):3352-3361.
33. Basso G, Veltroni M, Valsecchi MG, et al. Risk of relapse of childhood acute lym- phoblastic leukemia is predicted by flow cytometric measurement of residual dis- ease on day 15 bone marrow. J Clin Oncol. 2009;27(31):5168-5174.
34. Möricke A, Zimmermann M, Valsecchi MG, et al. Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000. Blood. 2016;127(17):2101-2112.
35. Kaplan EL, Meier P. Nonparametric estima- tion from incomplete observations. J Am Stat Assoc. 1958;53(282):457-481.
36. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50(3):163-170.
37. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data (ed 1). New York: John Wiley and sons. 1980:163-188.
38. Gray RJ. A class of K-sample tests for com- paring the cumulative incidence of a com- peting risk. Ann Stat. 1988;16(3):1141- 1154.
39. Weston BW, Hayden MA, Roberts KG, et al. Tyrosine kinase inhibitor therapy induces remission in a patient with refrac- tory EBF1PDGFRB-positive acute lym- phoblastic leukemia. J Clin Oncol. 2013;31(25):413-416.
40 Lengline E1, Beldjord K, Dombret H, Soulier J, Boissel N, Clappier E. Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lym- phoblastic leukemia with EBF1-PDGFRB fusion. Haematologica. 2013;98(11):146- 148.
1894
haematologica | 2020; 105(7)